Ropinirole: Current status of the studies

Journal of Neurology, Supplement

Volumn 251, Issue 6, 2004, Pages

  Jost, Wolfgang H ^a  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

Dopamine agonists; Parkinson's disease; Restless legs syndrome; Ropinirole

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; LEVODOPA; LISURIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

BRADYKINESIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIZZINESS; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FATIGUE; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RETROPERITONEAL FIBROSIS; RIGOR; TREMOR; VALVULAR HEART DISEASE;

BROMOCRIPTINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; LEVODOPA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 5644302354     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-1604-8     Document Type: Conference Paper

References (60)

1. Adler CH, Sethi KD, Hauser RA, et al. (1997) Ropinirole for the treatment of early Parkinson's disease. Neurology 49:393-399
2. Adler CH, Hauser RA, Sethi K, et al. (2004) Ropinirole for restless legs syndrome. Neurology 62:1405-1407
3. Anca MH, Giladi N, Korczyn AD (2004) Ropinirole in Gilles de la Tourette syndrome. Neurology 62:1626-1627
4. Anonymus (2002) DA agonists - nonergot derivates: Ropinirole. Mov Disord 17(Suppl 4):S98-S102
5. Barth F, Baum B, Meuser T, et al. (2004) Direkte und indirekte Kosten der Parkinson-Therapie. Fortschr Neurolog Psychiat (in press)
6. Bonucelli U (2003) Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 16(Suppl 1): S13-S19
7. Brooks DJ, Torjanski N, Burn DJ (1995) Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 45(Suppl):231-238
8. 2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 21:101-107
9. Brooks DJ (2003) Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol 53(Suppl 3):S110-S119
10. Brunt ER, Brooks DJ, Korczyn AD, et al. (2002) A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 109:489-502
11. Canesi M, Antonini A, Mariani CB, et al. (1999) An overnight switch to ropinirole therapy in patients with Parkinson's disease. J Neural Transm 106:925-929
12. Clarke CE, Deane KHO (2001) Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2:CD001517
13. Clarke CE, Guttman M (2002) Dopamine agonist monotherapy in Parkinson's disease. Lancet 360:1767-1769
14. Cristina S, Zangaglia R, Mancini F, et al. (2003) High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol 26:146-150
15. Elble RJ (2002) Tremor and dopamine agonists. Neurology 58(Suppl 1): S57-S62
16. Freeman A, Rye DB, Bliwise D, et al. (2001) Ropinirole for the restless legs syndrome (RLS): an open-label and double-blind placebo-controlled study. Neurology 56(Suppl 3):A5
17. Frucht S, Rogers JD, Greene PE, et al. (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908-1910
18. Garcia-Borreguero D, Odin P, Schwarz C (2004) Restless legs syndrome: an overview of the current understanding and management. Acta Neurol Scand 109:303-317
19. Giménez-Roldán S, Esteban EM, Mateo D (2001) Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different doseration. Clin Neuropharmacol 24: 346-351
20. Goetz CG, Blasucci L, Stebbins GT (1999) Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology 52:1227-1229
21. Goldberg JF, Burdick KE, Endick CJ (2004) Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 161:564-566
22. Grosset KA, Grosset DG (2004) Pergolide in Parkinson's disease: time for a change? Lancet 363:1907-1908
23. Horvath J, Fross RD, Kleiner-Fisman G, et al. (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656-662
24. Hubble J, Koller WC, Atchison P, et al. (2000) Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease. J Clin Pharmacol 40:641-646
25. Im JH, Ha JH, Cho IS, Lee MC (2003) Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease. A 16-week bromocriptine controlled study. J Neurol 250:90-96
26. Inzelberg R, Schechtman E, Nisipeanu O (2003) Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease. Drugs Aging 20:847-855
27. Iskedjian M, Einarson TR (2003) Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. Pharmacoeconomics 21:115-127
28. Jost WH (1999) Equivalent doses of ropinirole and bromocriptine. Eur J Neurol 6:618
29. 3-receptors: from anatomy to neuropsychiatry. NeuroScience News 2:11-21
30. Kaye CM, Nicholls B (2000) Clinical pharmacokinetics of ropinirole. Clin Pharmakokinet 39:243-254
31. Korczyn AD, Brooks D, Brunt ER, et al. (1998) Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 13:46-51
32. Korczyn AD, Brunt ER, Larsen JP, et al. (1999) A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology 53:364-370
33. Korczyn AD, Thalamas C, Adler CH (2002) Dosing with ropinirole in a clinical setting. Acta Neurol Scand 106:200-204
34. Korczyn AD, Rascol O, De Deyn P, Watts R, Lang A (2004) An 8.5-year follow-up of patients with early Parkinson's disease initially receiving ropinirole or L-dopa. Unpublished data
35. Lemke MR (2002) Depression und Morbus Parkinson. Uni-Med Verlag, Bremen, pp 52-53
36. Lieberman A, Olanow CW, Sethi K, et al. (1998) A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 51:1057-1062
37. Matheson AJ, Spencer CM (2000) Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 60:115-137
38. Millan MJ, Maiofiss L, Cussac D, et al. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791-804
39. Müngersdorf M, Sommer U, Sommer M, Reichmann H (2001) High-dose therapy with ropinirole in patients with Parkinson's disease. J Neural Transm 108:1309-1317
40. 2 - adrenoreceptor. J Pharmacol Exp Therap 303:805-814
41. 2, receptor subtypes. J Pharmacol Exp Therap 303:815-822
42. Ondo W (1999) Ropinirole for restless legs syndrome. Mov Disord 14:138-140
43. Paus S, Brecht HM, Köster J, et al. (2003) Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 18: 659-667
44. Pearce RKB, Banerji T, Jenner P, Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13:234-241
45. Perugi G, Toni C, Ruffolo G, et al. (2001) Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 34:137-141
46. Pluck GC, Brown RG (2002) Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 73:636-642
47. Rascol O, Lees AL, Senard JM, et al. (1996) Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clinical Neuropharmacology 19:234-245
48. Rascol O, Brooks DJ, Korczyn AD, et al. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484-1491
49. Rogers DC, Costall B, Domeney AM, et al. (2000) Anxiolytic profile of ropinirole in the rat, mouse and common marmoset. Psychopharmacology (Berl) 151:91-97
50. Saletu B, Gruber G, Saletu M, et al. (2000) Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 41:181-189
51. Saletu M, Anderer P, Saletu B, et al. (2001) Sleep laboratory studies in periodic limb movement disorder (PLMD) patients as compared with normals and acute effects of ropinirole. Hum Psychopharmacol 16:177-187
52. Schrag AE, Brooks DJ, Brunt E, et al. (1998) The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol 21:169-175
53. Schrag A, Keens J, Warner J (2002) Ropinirole for the treatment of tremor in early Parkinson's disease. Eur J Neurol 9:253-257
54. Sethi KD, O'Brien CF, Hammerstad JP, et al. (1998) Ropinirole for the treatment of early Parkinson disease. Arch Neurol 1998:1211-1216
55. Schapira AHV (2002) Neuroprotection and dopamine agonists. Neurology 58(Suppl 1):S9-18
56. Stocchi E, Vacca L, Berardelli A (2003) Dual dopamine agonist treatment in Parkinson's disease. J Neurol 250:822-826
57. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. (2004). Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomized, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75:92-97
58. Tulloch IF (1997) Pharmacologic profile of ropinirole. Neurology 49(Suppl 1):S58-S62
59. Whone AL, Watts RL, Stoessl AJ, et al. (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93-101
60. rd, Simon NM, Korbly NB, et al. (2002) Ropinirole for antidepressant-induced sexual dysfunction. Int Clin Psychopharmacol 17:307-310